The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures, demographic information, cognitive function, genetic sequence information (genomic), chemical measures of metabolism (metabolomic), protein makeup (proteomic) and the body's natural defence system (immune/inflammatory markers) together with collections of cells that will facilitate new research to drive improvements in diagnosis and treatment of mood disorders that may be proving difficult to treat. This will allow future clinical trials within the NHS, academia and industry to drive forward new approaches and treatments. Participants who provide consent for re-contact for future treatment trials and other research studies have the potential to benefit from this with participation in experimental studies and clinical trials associated with improved patient outcomes. Overall, the cohort will generally support greater access to research opportunities for a wider population of people.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
PHQ-9
Timeframe: Up to 36 months.